The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Andrew G. Nicholson; Ming‐Sound Tsao; Mary Beth Beasley; Alain Borczuk; Élisabeth Brambilla; Wendy A. Cooper; Sanja Đačić; Deepali Jain; Keith M. Kerr; Sylvie Lantuéjoul; Masayuki Noguchi; Mauro Papotti; Natasha Rekhtman; Giorgio V. Scagliotti; Paul Van Schil; Lynette M. Sholl; Yasushi Yatabe; Akihiko Yoshida; William D. Travis

doi:10.1016/j.jtho.2021.11.003

Keywords

MedicineGrading (engineering)SMARCA4PathologyImmunohistochemistryLungAdenomaInternal medicineBiology

Affiliated Institutions

Related Publications

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez , Pasi A. Jänne , Jeffrey C. Lee +14 more

Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGF...

2004 Science 9327 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao , Vincent A. Miller , Maureen F. Zakowski +12 more

Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib ...

2004 Proceedings of the National Academy o... 4316 citations

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis , Arie Perry , Pieter Wesseling +10 more

Abstract The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the...

2021 Neuro-Oncology 10245 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive<i>p53</i>Gene Mutations in Squamous Cell Carcinoma of the Head and Neck

William H. Westra , Janis M. Taube , Maria Luana Poeta +3 more

Abstract Purpose: Squamous cell carcinomas of the head and neck (HNSCC) often harbor p53 mutations, but p53 protein degradation by the viral oncoprotein E6 may supercede p53 mut...

2008 Clinical Cancer Research 230 citations

Publication Info

Year: 2021
Type: review
Volume: 17
Issue: 3
Pages: 362-387
Citations: 1254
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1254

OpenAlex

Cite This

APA Style

                            
                                
                                    Andrew G. Nicholson, 
                                
                                    Ming‐Sound Tsao, 
                                
                                    Mary Beth Beasley
                                
                                et al.
                            
                            (2021). 
                            The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. 
                            Journal of Thoracic Oncology
                            , 17
                            (3)
                            , 362-387.
                            https://doi.org/10.1016/j.jtho.2021.11.003
                        

Identifiers

DOI: 10.1016/j.jtho.2021.11.003